Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA4 | P22748 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6630434 | 1.00 | CA1 (0.40) | CA1CA2CA4CA9BRD4 | |
| SCHEMBL28896124 | 0.89 | CA1 (0.33) | CA1CA2CA4CA9BRD4 | |
| SCHEMBL21039807 | 0.85 | CA1 (0.32) | CA1CA2CA4CA9 | |
| SCHEMBL1190470 | 0.83 | — | — | |
| SCHEMBL1184002 | 0.83 | — | — | |
| SCHEMBL1183999 | 0.83 | — | — | |
| SCHEMBL5178738 | 0.83 | TSHR (0.32) | CA1CA2CA4CA9 | |
| SCHEMBL2920965 | 0.82 | CA1 (0.33) | CA1CA2CA4CA9 | |
| SCHEMBL9975344 | 0.82 | SLC6A3 (0.32) | — | |
| SCHEMBL7907918 | 0.82 | SLC6A3 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1077931-B1 | BENZAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | ASTRAZENECA AB (SE) | 2004-11-17 | — | — | EP | claimed |
| EP-1418916-A1 | 2-AMINO-4-HETEROARYLAMINOPYRIMIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | Amgen Inc. (US) | 2004-05-19 | — | — | EP | claimed |
| WO-2003018022-A1 | 2-AMINO-4-HETEROARYLAMINOPYRIMIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | AMGEN INC. (US) | 2003-03-06 | — | — | WO | claimed |
| CN-116947890-A | Tricyclic compound of WEE1 inhibitor, and preparation method and application thereof | 星希尔生物科技(上海)有限公司 | 2023-10-27 | — | — | CN | disclosed |
| WO-2023001061-A1 | CDK7 SELECTIVE INHIBITORS AS ANTICANCER AGENTS | JINGRUI BIOPHARMA CO., LTD. (CN) | 2023-01-26 | — | — | WO | disclosed |
| US-9034850-B2 | Gonadotropin releasing hormone receptor antagonist, preparation method thereof and pharmaceutical composition comprising the same | SK CHEMICALS CO., LTD. (KR) | 2015-05-19 | — | — | US | disclosed |
| US-20130137661-A1 | Gonadotropin Releasing Hormone Receptor Antagonist, Preparation Method Thereof And Pharmaceutical Composition Comprising The Same | SK CHEMICALS CO. LTD. (KR) | 2013-05-30 | — | — | US | disclosed |
| US-7858796-B2 | Chemical compounds | GLAXO GROUP LIMITED (GB) | 2010-12-28 | — | — | US | disclosed |
| US-7858796-B2 | Chemical compounds | GLAXO GROUP LIMITED (GB) | 2010-12-28 | — | — | US | disclosed |
| EP-2010528-A2 | 6-O-SUBSTITUTED BENZOXAZOLE AND BENZOTHIAZOLE COMPOUNDS AND METHODS OF INHIBITING CSF-1R SIGNALING | Novartis Pharma AG (CH) | 2009-01-07 | — | — | EP | disclosed |
| US-7405217-B2 | N-aroyl piperazine derivatives as orexin receptor antagonists | SMITHKLINE BEECHAM P.L.C. (GB) | 2008-07-29 | — | — | US | disclosed |
| US-20070167457-A1 | N-AROYL PIPERAZINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC | 2007-07-19 | — | — | US | disclosed |
| US-7166608-B2 | N-aroyl piperazine derivatives as orexin receptor antagonists | SMITHKLINE BEECHAM P.L.C. (GB) | 2007-01-23 | — | — | US | disclosed |
| EP-0972775-B1 | PYRROLOINDOLE DERIVATIVES AND INTERMEDIATES IN PRODUCING THE SAME | KYORIN SEIYAKU KK (JP) | 2004-12-08 | — | — | EP | disclosed |
| EP-1427421-A1 | 2,4-DISUBSTITUTED PYRIMIDINYL DERIVATIVES FOR USE AS ANTICANCER AGENTS | Amgen Inc. (US) | 2004-06-16 | — | — | EP | disclosed |
| EP-1332141-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2003-08-06 | — | — | EP | disclosed |
| WO-2003018021-A1 | 2,4-DISUBSTITUTED PYRIMIDINYL DERIVATIVES FOR USE AS ANTICANCER AGENTS | AMGEN INC. (US) | 2003-03-06 | — | — | WO | disclosed |
| WO-2002034744-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-05-02 | — | — | WO | disclosed |
| US-6080859-A | 1-CHLOROMETHYL, 3-((HETEROARYL OR ARYL)CARBONYL), 5-(HETEROCYCLE-AMINOCARBONYLOXY),7-TRIFLUOROMETHYL, 8-ALKOXYCARBONYL-1,2,3,6-TETRAHYDROPYRROLO(3,2-E)INDOLE OF GIVEN STRUCTURE; ANTITUMOR AND ANTIMICROBIAL ACTIVITY | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2000-06-27 | — | — | US | disclosed |
| EP-0972775-A1 | PYRROLOINDOLE DERIVATIVES AND INTERMEDIATES IN PRODUCING THE SAME | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2000-01-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137661-A1 | Gonadotropin Releasing Hormone Receptor Antagonist, Preparation Method Thereof And Pharmaceutical Composition Comprising The Same | GNRHR, GHRHR, LHCGR | CA1 2830/4885CA2 2425/4885CA4 1923/4885 |
| US-20070167457-A1 | N-AROYL PIPERAZINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPSR1 | CA1 1382/4885CA2 1036/4885CA4 3241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.